Stay updated on CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial
Sign up to get notified when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FkfsokZdEYQnUvvn8hNeGnkjt7PQ.uncropped.jpg&w=3840&q=75)
Latest updates to the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has expanded to include 10 locations and has been updated to revision v2.10.0, replacing the previous revision v2.9.7.SummaryDifference0.6%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Revision: v2.9.0' has been updated to 'Genetic and Rare Diseases Information Center resources: Lymphosarcoma Peripheral T-cell Lymphoma FDA Drug and Device Resources' in the latest revision v2.9.1.SummaryDifference18%
Stay in the know with updates to CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.